A phase 1 study of the Janus kinase 2 (JAK2)V617F inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia

Autor: Verstovsek, Srdan, Mesa, Ruben A., Salama, Mohamed E., Li, Li, Pitou, Celine, Nunes, Fabio P., Price, Gregory L., Giles, Jennifer L., D’Souza, Deborah N., Walgren, Richard A., Prchal, Josef T.
Zdroj: In Leukemia Research October 2017 61:89-95
Databáze: ScienceDirect
Externí odkaz: